Log In Sign up
The largest database of trusted experimental protocols
> Disorders > Disease or Syndrome > Diabetic Ketoacidosis

Diabetic Ketoacidosis

Diabetic ketoacidosis is a life-threatening complication of diabetes mellitus characterized by the buildup of acidic ketone bodies in the blood.
It occurs when the body is unable to use glucose for energy and starts breaking down fat instead, producing ketones that accumulate and cause the blood to become acidic.
Symptoms include excessive urination, excessive thirst, nausea, vomiting, and abdominal pain.
Prompt treatment with insulin and fluids is crucial to restore the body's chemical balance and prevent serious complications like coma or even death.
Proper management and prevention of diabetic ketoacidosis is an important aspect of diabeteis care. *Learn how PubCompare.ai can help optimizde your research protocols for diabetec ketoacidosis today.

Most cited protocols related to «Diabetic Ketoacidosis»

1
Expanding PheWAS Phenotype Categorization
In this study, we revised and expanded our earlier PheWAS phenotype categorization to a total of 1,645 phenotypes identified from International Classification of Disease, Ninth revision, Clinical Modification (ICD9) codes. (Our initial PheWAS phenotype categorization included 744 phenotypes9 (link).) The ICD9 coding system is divided into four components: diseases, signs and symptoms (“three digit” codes, 001–999), external causes of injury (“E” codes), procedures (“two digit” codes 00.0–99.9) and supplemental classifications (“V” codes). The prior PheWAS code groupings included only diseases, signs and symptoms (three digit) ICD9 codes9 (link). We revised and expanded the PheWAS phenotypes by (i) adding V codes (commonly used to record personal histories of given diseases) and E codes (which refer to external causes of injury) to the PheWAS code mapping, (ii) redesigning the code system to be hierarchical, such that one phenotype could be a parent of another subphenotype (e.g., cardiac arrhythmias is a parent of atrial fibrillation, atrial flutter and other arrhythmias), and (iii) including more granular phenotypes into the coding system (e.g., “type 1 diabetes with ketoacidosis”). Creation of hierarchical phenotypes included creation of phenotypes not present in the ICD9 billing hierarchy, such as “inflammatory bowel disease” as the parent phenotype for “Crohn’s disease” and “ulcerative colitis.” In this process, we were guided by the hierarchical organization of the Clinical Classifications Software (CCS) produced by the Agency for Healthcare Research and Quality42 (link); the 2011 version of the CCS contains 727 phenotypes. The resulting PheWAS code group currently contains 1,645 phenotypes, 1,358 of which had at least 25 cases (a prevalence of 0.18% in our data set) in the eMERGE cohort, our threshold for these analyses. The current version of the PheWAS codes, with ICD9 mappings and control groups, is available from http://knowledgemap.mc.vanderbilt.edu/research/content/phewas.
Denny J.C., Bastarache L., Ritchie M.D., Carroll R.J., Zink R., Mosley J.D., Field J.R., Pulley J.M., Ramirez A.H., Bowton E., Basford M.A., Carrell D.S., Peissig P.L., Kho A.N., Pacheco J.A., Rasmussen L.V., Crosslin D.R., Crane P.K., Pathak J., Bielinski S.J., Pendergrass S.A., Xu H., Hindorff L.A., Li R., Manolio T.A., Chute C.G., Chisholm R.L., Larson E.B., Jarvik G.P., Brilliant M.H., McCarty C.A., Kullo I.J., Haines J.L., Crawford D.C., Masys D.R, & Roden D.M. (2013). Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. Nature biotechnology, 31(12), 1102-1110.
Publication 2013
Atrial Fibrillation Atrial Flutter Cardiac Arrhythmia Crohn Disease Diabetic Ketoacidosis Fingers Inflammatory Bowel Diseases Injuries Parent Phenotype Ulcerative Colitis
2
Dementia Knowledge Assessment Scale (DKAS)
The DKAS [17 (link), 23 (link)] comprises statements about the syndrome that are factually correct or incorrect, which were developed on the basis of a literature review and international Delphi study with dementia experts [22 (link)]. Respondents answer on a modified Likert scale with five response options: false, probably false, probably true, true, don’t know. Preliminary PCA identified four hypothesised components/subscales within the measure that have been defined as Causes and Characteristics (dementia pathology and terminal course), Communication and Behaviour (how a person with dementia engages with the world), Care Considerations (dementia symptoms relevant to the provision of care), and Risks and Health Promotion (risk factors and conditions that are associated with or mistaken for dementia) [23 (link)].
Annear M.J., Toye C., Elliott K.E., McInerney F., Eccleston C, & Robinson A. (2017). Dementia knowledge assessment scale (DKAS): confirmatory factor analysis and comparative subscale scores among an international cohort. BMC Geriatrics, 17, 168.
Publication 2017
Diabetic Ketoacidosis Health Promotion Presenile Dementia Syndrome
3
Type 2 Diabetes Outpatient Protocol
The study enrolled 340 outpatients with type 2 diabetes managed at any of the 51 participating clinics in Japan. The full list of study investigators is provided in Additional file 1. Enrollment began in July 2017 and ended in June 2018. The inclusion criteria were as follows: (1) patients with type 2 diabetes who had not used any glucose-lowering agents within 8 weeks before consenting, or those who had used only metformin; (2) those with HbA1c (NGSP values) levels of ≥ 7.1% (54 mmol/mol) but not > 10.0% (86 mmol/mol); (3) those aged between 20 and 80 years; (4) those with body mass index (BMI) of ≥ 23 kg/m2; (5) those who could be monitored closely for medication compliance; and (6) those who provided written consent to participate in the study. The following exclusion criteria were used: (1) patients with type 1 diabetes or secondary diabetes; (2) those with a medical history of diabetic ketoacidosis; (3) those with a medical history of myocardial infarction, cerebral infarction, or stroke within 12 weeks before consenting to the study; (4) those with severe liver disease having more than fivefold higher than normal levels of AST and ALT; (5) those with renal disease [serum creatinine ≥ 1.3 mg/dL, or estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73 m2]; (6) those with unstable hypertension or dyslipidemia within 12 weeks before consent to the study; (7) those who were pregnant or breastfeeding or were planning to become pregnant during the study; and (8) dehydrated patients [test results showed abnormalities in hematocrit or blood urea nitrogen (BUN) or patient complaints of dehydration].
Fuchigami A., Shigiyama F., Kitazawa T., Okada Y., Ichijo T., Higa M., Hiyoshi T., Inoue I., Iso K., Yoshii H., Hirose T, & Kumashiro N. (2020). Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR). Cardiovascular Diabetology, 19, 1.
Publication 2020
Cerebral Infarction Cerebrovascular Accident Congenital Abnormality Creatinine Dehydration Diabetes Mellitus Diabetes Mellitus, Insulin-Dependent Diabetes Mellitus, Non-Insulin-Dependent Diabetic Ketoacidosis Dyslipidemias Glomerular Filtration Rate Glucose High Blood Pressures Index, Body Mass Kidney Diseases Liver Diseases Metformin Myocardial Infarction Outpatients Patients Serum Urea Nitrogen, Blood Volumes, Packed Erythrocyte
4
Genetic Comparison of African Americans with Type 2 Diabetes
The AA-DHS contained AAs with T2DM recruited from two Wake Forest School of Medicine (WFSM) studies: the Diabetes Heart Study (DHS) and African American-DHS. DHS is a cross-sectional study of EA and AA families with siblings concordant for T2DM. AA-DHS started after DHS and enrolled only unrelated AAs. AA-DHS objectives were to improve understanding of the striking ethnic differences in CAC observed between AAs and EAs. T2DM was diagnosed after the age of 30 years in the absence of diabetic ketoacidosis. The DHS “family of studies” is described in Bowden et al.13 (link). Subjects who underwent prior coronary artery bypass surgery were not included in the MALD analysis, as the CAC mass score could be impacted14 (link). Those with prior myocardial infarction or stroke were included. The final analysis included 635 unrelated AAs obtained by selecting all AA-DHS participants and one AA from each of 150 DHS sibpairs (the sibling with the most complete phenotypic data and best kidney function). The study was approved by the WFSM Institutional Review Board; all participants provided written informed consent.
Divers J., Palmer N.D., Lu L., Register T.C., Carr J.J., Hicks P.J., Hightower R.C., Smith S.C., Xu J., Cox A.J., Hruska K.A., Bowden D.W., Lewis C.E., Heiss G., Province M.A., Borecki I.B., Kerr K.F., Chen Y.D., Palmas W., Rotter J.I., Wassel C.L., Bertoni A., Herrington D., Wagenknecht L.E., Langefeld C.D, & Freedman B.I. (2012). Admixture Mapping of Coronary Artery Calcified Plaque in African Americans with Type 2 Diabetes. Circulation. Cardiovascular genetics, 6(1), 97-105.
Publication 2012
African American Cerebrovascular Accident Coronary Artery Bypass Surgery Diabetes Mellitus Diabetic Ketoacidosis Ethics Committees, Research Forests Heart Kidney Myocardial Infarction Pharmaceutical Preparations Phenotype
5
Self-Reported Diabetes Features in UK Biobank
Features of diabetes, including age of diagnosis, insulin use within 1 year of diagnosis, and insulin use at enrolment to the study, were self-reported via an interactive questionnaire completed at baseline enrolment into UK Biobank. Self-reported diabetes diagnosis has been shown to have a high accuracy compared with use of primary health records.22 (link) Anthropometric measurements were collected at baseline when participants attended the assessment centre. We used the BMI recorded in UK Biobank, calculated as (weight [kg]/height [m]2). Gender was self-reported. Results were coded as missing if individuals had answered “don't know” or “prefer not to answer”. Records with inconsistencies in the data were removed (appendix).
Admissions for primary or secondary diabetic ketoacidosis were identified by use of diagnosis codes from hospital admissions data between April 1, 1997, and March 31, 2015. Diagnoses were coded according to the International Classification of Diseases version 10 (appendix).
Thomas N.J., Jones S.E., Weedon M.N., Shields B.M., Oram R.A, & Hattersley A.T. (2018). Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank. The Lancet. Diabetes & Endocrinology, 6(2), 122-129.
Publication 2018
Diabetes Mellitus Diabetic Ketoacidosis Diagnosis Gender Insulin

Most recents protocols related to «Diabetic Ketoacidosis»

1
Circulating RNA Profiles in Early-Onset Type 1 Diabetes
A total of 240 individuals were placed into two cohorts, and Table 1 shows the clinical and demographic data of these individuals. We selected five patients with new onset FT1D (median diabetes duration one month) and five age- and sex-matched control individuals for analysis in the first cohort. In the second cohort, 115 patients with FT1D (N = 40) or T1D (N = 75) and 115 controls were recruited to validate differentially expressed circRNAs identified in the first cohort.
Patients with diabetes met the diagnostic criteria of the American Diabetes Association (15 (link)). Individuals with T1D were recruited based on the following criteria: (1) acute onset of ketosis or ketoacidosis requiring insulin replacement therapy; (2) at least six months of continuous insulin dependence after diagnosis; and (3) positive glutamic acid decarboxylase antibodies (GADAs). Diagnosis of FT1D was performed according to the criteria of the Committee of the Japan Diabetes Society in 2012 (16 (link)). The inclusion criteria for FT1D were as follows (1): occurrence of diabetic ketosis or ketoacidosis within a week after onset of hyperglycemic symptoms; (2) initial PG level > 16.0 mmol/L and HbA1c < 8.7% (72 mmol/mol) at onset; and (3) serum FCP < 100 pmol/L (0.3 ng/ml) and PCP < 170 pmol/L (0.5 ng/ml) at disease onset. Controls had fasting plasma glucose (FPG) < 5.6 mmol/L and HbA1c < 6.1%. The exclusion criteria for control subjects were infectious diseases, pregnancy, malignant disease, or a family history of diabetes.
All data were collected from patients from the Second Xiangya Hospital of Central South University (Changsha, Hunan, China). The study was approved by the Ethical Committee of the Second Xiangya Hospital of Central South University (LYF 2021100), and all subjects provided written informed consent prior to inclusion in the study.
Yin W., Luo S., Qiu J., Xiao Z., Zhang Z., Xie Z., Li X, & Zhou Z. (2023). Identification of hsa_circRNA_100632 as a novel molecular biomarker for fulminant type 1 diabetes. Frontiers in Immunology, 14, 1075970.
Publication 2023
Antibodies Communicable Diseases Diabetes Mellitus Diabetic Ketoacidosis Diagnosis Gender Glucose Glutamate Decarboxylase Insulin Ketosis Patients Plasma Pregnancy RNA, Circular Serum Therapy, Hormone Replacement
2
Retrospective Cohort Study of Type 2 Diabetes
Participants aged 18 to 80 were chronologically and retrospectively recruited from Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University from January, 2011 to January 2021. Initially, a total of 16,589 patients with type 2 diabetes mellitus were enrolled in this study. After screening, 13,757 patients were excluded for the following reasons: (i) receiving renal replacement therapies; (ii) having a definite diagnosis of nondiabetic kidney disease; (iii) having diabetic acute complications, such as diabetic ketoacidosis or hyperosmolar hyperglycemic coma; (iv) having chronic diseases that may affect metabolic function, including hypothalamic disease, adrenal disease, any thyroid medication (levothyroxine or antithyroid medication), or a history of thyroid diseases prior to diabetes mellitus; (v) having severe respiratory, digestive, or hematological diseases, or current acute or severe infections, autoimmune diseases, or malignancies; (vi) lacking necessary information, such as serum creatinine and urinary albumin-to-creatinine ratio (UACR). Finally, total 2,832 eligible patients were enrolled in the present study, including 1,710 males and 1,122 females.
Liu M.C., Li J.L., Wang Y.F., Meng Y., Cai Z., Shen C., Wang M.D., Zhao W.J, & Niu W.Q. (2023). Association between thyroid hormones and diabetic kidney disease in Chinese adults. BMC Endocrine Disorders, 23, 56.
Publication 2023
Adrenal Gland Diseases Albumins Antithyroid Agents Autoimmune Diseases Complications of Diabetes Mellitus Creatinine Diabetes Mellitus Diabetes Mellitus, Non-Insulin-Dependent Diabetic Ketoacidosis Diagnosis Digestive System Disease, Chronic Females Hematological Disease Hyperglycemic Hyperosmolar Nonketotic Coma Hypothalamic Diseases Infection Kidney Diseases Males Malignant Neoplasms Patients Pharmaceutical Preparations Renal Replacement Therapy Respiratory Rate Serum Thyroid Diseases Thyroid Gland Thyroxine Urine
3
Epidemiology of Diabetic Kidney Disease
This study was approved by the Ethics Committee of the Affiliated Hospital of Nanjing University of Chinese Medicine (2019NL-I09-02). Written informed consent was obtained from each participant prior to their enrollment. This study was conducted in accordance with Helsinki Declaration of 1964 and its later amendments. This study was registered in the Chinese Clinical Trial Registration Center (ChiCTR2000028949).
In this cross-sectional study, 993 Chinese patients aged 20–75 years with T2D and DKD were recruited from March 2019 to June 2020 in the Diabetes Clinic of the Department of Endocrinology at the Affiliated Hospital of Nanjing University of Chinese Medicine. Patients with persistently elevated urine albumin excretion (UACR ≥ 30 mg/g), persistently reduced eGFR (< 60 mL/min/1.73 m2) or both were considered eligible for inclusion in the study. Individuals were excluded if they were missing pre-baseline UACR data (n = 95); if they had UACR < 30 mg/g within 6 months prior to baseline measurement (n = 47); if they had diabetic ketoacidosis (n = 3); if they were diagnosed with an urinary tract infection, hematuria or other kidney disease (n = 71); or if they had a history of cancer (n = 9).
Zhu L., Wang X., Sun J., Qian Q., Yu J, & An X. (2023). Hyperuricemia Predicts the Progression of Type 2 Diabetic Kidney Disease in Chinese Patients. Diabetes Therapy, 14(3), 581-591.
Publication 2023
Albumins Chinese Diabetes Mellitus Diabetic Ketoacidosis EGFR protein, human Ethics Committees, Clinical Hematuria Kidney Diseases Malignant Neoplasms Patients Pharmaceutical Preparations System, Endocrine Urinary Tract Infection Urine
4
Cross-sectional Study of Diabetes Patients
This cross-sectional study was conducted among patients attending the outpatient department of the Department of Internal Medicine of Shree Birendra Hospital, Kathmandu, Nepal from 1 November 2020 to 30 May 2021. Patients above 18 years of age on antidiabetes medications or recently diagnosed DM based on American Diabetes Association criteria10 were included in the study. The patients excluded in the study were patients with diabetes on insulin as the first-line treatment or those anticipated to require insulin within the first year of diagnosis, history of diabetic ketoacidosis any history suggestive of previous renal disorders or documented renal pathology, pregnant women and critically ill patients. A total of 201 patients were enrolled in our study based on such criteria (figure 1). This study was conducted in accordance with the guidelines of Strengthening of the Reporting of Observational Studies in Epidemiology.
Joshi R., Subedi P., Yadav G.K., Khadka S., Rijal T., Amgain K, & Rajbhandari S. (2023). Prevalence and risk factors of chronic kidney disease among patients with type 2 diabetes mellitus at a tertiary care hospital in Nepal: a cross-sectional study. BMJ Open, 13(2), e067238.
Publication 2023
Critical Illness Diabetes Mellitus Diabetic Ketoacidosis Diagnosis Insulin Kidney Kidney Diseases Outpatients Patients Pharmaceutical Preparations Pregnant Women
5
Cerebral Injury Patients Receiving EN
We selected adult patients admitted to the NSICU from January 2021 to May 2022 using convenience sampling. The inclusion and exclusion criteria for this study are as follows. Inclusion criteria: (1 (link)) diagnosed with cerebral hemorrhage, intracranial aneurysm, subarachnoid hemorrhage, or acute craniocerebral injury by cranial computed tomography (CT) or magnetic resonance imaging (MRI); (2 (link)) received EN for >72 h during admission to NSICU; (3 (link)) biochemical test results, including serum phosphorus, before and after EN (within 72 h). Exclusion criteria: (1 (link)) incomplete data; (2 (link)) aged >80 years or <18 years; (3 (link)) serum phosphorus <0.65 mmol/L before admission to NSICU; (4 (link)) end-stage malignant tumor; (5 (link)) acute respiratory alkalosis, metabolic alkalosis, or diabetic ketoacidosis; (6 (link)) presence of other risk factors for hypophosphatemia, such as continuous hemodialysis, hyperphosphatemia treatment, and parathyroidectomy within the last 3 months.
Zhang W., Zhang S.X., Chen S.F., Yu T, & Tang Y. (2023). Development and validation of risk prediction model for refeeding syndrome in neurocritical patients. Frontiers in Nutrition, 10, 1083483.
Publication 2023
Adult Alkalosis Alkalosis, Respiratory Cerebral Hemorrhage Craniocerebral Trauma Cranium Diabetic Ketoacidosis Hemodialysis Hyperphosphatemia Hypophosphatemia Intracranial Aneurysm Malignant Neoplasms Parathyroidectomy Patients Phosphorus Serum Subarachnoid Hemorrhage X-Ray Computed Tomography

Top products related to «Diabetic Ketoacidosis»

1
Streptozotocin (stz) by Merck Group
Sourced in United States, Germany, China, Sao Tome and Principe, United Kingdom, India, Japan, Macao, Canada, France, Italy, Switzerland, Egypt, Poland, Hungary, Denmark, Indonesia, Singapore, Sweden, Belgium, Malaysia, Israel, Spain, Czechia
STZ is a laboratory equipment product manufactured by Merck Group. It is designed for use in scientific research and experiments. The core function of STZ is to serve as a tool for carrying out specific tasks or procedures in a laboratory setting. No further details or interpretation of its intended use are provided.
2
Spss version by IBM
Sourced in United States, United Kingdom, Japan, Germany
SPSS is a software package used for statistical analysis. It provides a graphical user interface and a robust set of tools for data manipulation, analysis, and visualization. SPSS is designed to handle a wide range of data types and supports a variety of statistical techniques, including regression analysis, factor analysis, and time series analysis.
3
Spss amos by IBM
Sourced in United States
SPSS Amos is a statistical software package designed for conducting structural equation modeling (SEM) analysis. It provides a graphical user interface for building, estimating, and validating SEM models. SPSS Amos enables users to explore the relationships between observed and latent variables, as well as to test hypotheses about these relationships.
4
129s1 svimj by Jackson ImmunoResearch
Sourced in United States, Montenegro, United Kingdom
The 129S1/SvImJ is a mouse strain that serves as a laboratory animal model. It is commonly used in research applications.
5
Modular p by Roche
Sourced in Germany, United States, Switzerland, United Kingdom
The Modular P is a versatile and automated laboratory instrument designed for clinical chemistry analysis. It features a modular design that allows for customization to meet the specific needs of a laboratory. The Modular P is capable of performing a wide range of clinical chemistry tests, including assays for enzymes, substrates, and electrolytes. The instrument is designed for high-throughput operation and can process a large number of samples efficiently.
6
B6129sf2 j by Jackson ImmunoResearch
Sourced in United States, Montenegro
B6129SF2/J is a laboratory mouse strain. It is a substrain of the B6 mouse strain.
7
Automated glycohemoglobin analyzer hlc 723g8 by Tosoh
Sourced in Japan
The Automated Glycohemoglobin Analyzer HLC-723G8 is a laboratory instrument designed to measure glycohemoglobin levels. It provides an automated and precise method for the quantitative determination of glycohemoglobin in human whole blood samples.
8
Penicillin by Merck Group
Sourced in United States, Germany, United Kingdom, Italy, France, Switzerland, Brazil, China, Poland, Macao, Spain, Canada, Japan, Australia, Austria, Belgium, Israel, Sao Tome and Principe, Netherlands, India, Sweden, Ireland, Argentina, Czechia, Denmark, New Zealand, Hungary, Mexico, Holy See (Vatican City State), Ukraine
Penicillin is a type of antibacterial drug that is widely used in medical and laboratory settings. It is a naturally occurring substance produced by certain fungi, and it is effective against a variety of bacterial infections. Penicillin works by inhibiting the growth and reproduction of bacteria, making it a valuable tool for researchers and medical professionals.
9
Accu chek performa by Roche
Sourced in Germany, United States, Switzerland, Australia, France, Brazil, China, Japan, Argentina, Thailand, United Kingdom, Canada
The Accu-Chek Performa is a blood glucose monitoring system designed to measure the level of glucose in the user's blood. It provides accurate and reliable readings to help individuals manage their diabetes.
10
Dedicated ion exchange high performance liquid chromatography instrument by Tosoh
The Dedicated ion exchange high-performance liquid chromatography instrument is a specialized laboratory equipment used for the separation and analysis of ionic compounds. It utilizes the principles of ion exchange chromatography to achieve high-performance liquid chromatography (HPLC) separation. The core function of this instrument is to facilitate the efficient separation, identification, and quantification of ionic analytes in complex samples.

More about "Diabetic Ketoacidosis"

Diabetic Ketoacidosis (DKA) is a serious complication of diabetes mellitus (DM) characterized by the buildup of acidic ketones in the blood.
When the body is unable to use glucose for energy, it starts breaking down fat, producing ketones that accumulate and cause the blood to become too acidic.
Symptoms include excessive urination, thirst, nausea, vomiting, and abdominal pain.
DKA is a life-threatening condition that requires prompt treatment with insulin and fluid replacement to restore the body's chemical balance and prevent complications like coma or even death.
Proper management and prevention of DKA is a crucial aspect of diabetes care.
Related terms and abbreviations include Streptozotocin (STZ), SPSS version, SPSS Amos, 129S1/SvImJ, Modular P, B6129SF2/J, Automated Glycohemoglobin Analyzer HLC-723G8, Penicillin, and Accu-Chek Performa.
A dedicated ion exchange high-performance liquid chromatography instrument may also be used in DKA research and treatment.
Optimizing research protocols for DKA is important to advance our understanding and management of this serious diabetic complication.
PubCompare.ai's AI-driven platform can help identify the best reproducible and accurate protocols from literature, preprints, and patents, leveraging advanced comparisons to find the optimal protocols and products for your DKA studies.